Initial tumor size predicts histologic response and survival in localized osteosarcoma patients

被引:45
作者
Kim, Min Suk [2 ]
Lee, Soo-Yong [1 ]
Cho, Wan Hyeong [1 ]
Song, Won Seok [1 ]
Koh, Jae-Soo [2 ]
Lee, Jun Ah [3 ]
Yoo, Ji Young [4 ]
Jeon, Dae-Geun [1 ]
机构
[1] Korea Canc Ctr Hosp, Dept Orthoped Surg, Seoul 139706, South Korea
[2] Korea Canc Ctr Hosp, Dept Pathol, Seoul 139706, South Korea
[3] Korea Canc Ctr Hosp, Dept Pediat, Seoul 139706, South Korea
[4] Korea Canc Ctr Hosp, Dept Radiol, Seoul 139706, South Korea
关键词
osteosarcoma; tumor volume; prognosis;
D O I
10.1002/jso.20986
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: To evaluate the correlation between histologic response and size parameters, and to analyze the prognostic importance of size parameters on metastasis-free survival in localized osteosarcoma patients. Methods: We retrospectively reviewed 331 patients with stage II osteosarcoma treated with surgery and chemotherapy. The tumor size parameters were measured and calculated based on MR images. The mean metastasis-firee interval was 77.8 months (range, 3-205 months; median, 67 months). Results: Tumor size is best defined by relative tumor plane (RTP). Patients with a large tumor (RTP>27.5 cm(2)/m(2)) had a significant correlation with poor histologic response and distal femoral tumor location. The independent prognostic factors for metastasis-free survival were American Joint Committee on Cancer (AJCC) stage, RTP, proximal humerus location, chondroblastic subtype, and poor histologic response. Conclusion: The initial tumor size is closely related to histologic response and is an important prognostic factor in osteosarcoma. Tumor size is best represented by AJCC stage and RTP. These parameters may serve as a basis for risk-adapted therapy in combined stratification with histologic response.
引用
收藏
页码:456 / 461
页数:6
相关论文
共 20 条
[1]
[Anonymous], 2002, American Joint Committee on Cancer Staging Manual
[2]
Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity - Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor [J].
Bacci, G ;
Bertoni, F ;
Longhi, A ;
Ferrari, S ;
Forni, C ;
Biagini, R ;
Bacchini, P ;
Donati, D ;
Manfrini, M ;
Bernini, G ;
Lari, S .
CANCER, 2003, 97 (12) :3068-3075
[3]
BACCI G, 1990, CANCER, V65, P2539, DOI 10.1002/1097-0142(19900601)65:11<2539::AID-CNCR2820651125>3.0.CO
[4]
2-M
[5]
Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].
Bielack, SS ;
Kempf-Bielack, B ;
Delling, G ;
Exner, GU ;
Flege, S ;
Helmke, K ;
Kotz, R ;
Salzer-Kuntschik, M ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Jürgens, H ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790
[6]
Tumor size and prognosis in aggressively treated osteosarcoma [J].
Bieling, P ;
Rehan, N ;
Winkler, P ;
Helmke, K ;
Maas, R ;
Fuchs, N ;
Bielack, S ;
Heise, U ;
Jurgens, H ;
Treuner, J ;
Romanowski, R ;
Exner, U ;
Kotz, R ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :848-858
[7]
Preoperative systemic treatment: prediction of responsiveness [J].
Colleoni, M ;
Zarieh, D ;
Gelber, RD ;
Viale, G ;
Luini, A ;
Veronesi, P ;
Intra, M ;
Galimberti, V ;
Renne, G ;
Goldhirsch, A .
BREAST, 2003, 12 (06) :538-542
[8]
A CONTROLLED PILOT-STUDY OF HIGH-DOSE METHOTREXATE AS POSTSURGICAL ADJUVANT TREATMENT FOR PRIMARY OSTEO-SARCOMA [J].
EDMONSON, JH ;
GREEN, SJ ;
IVINS, JC ;
GILCHRIST, GS ;
CREAGAN, ET ;
PRITCHARD, DJ ;
SMITHSON, WA ;
DAHLIN, DC ;
TAYLOR, WF .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (03) :152-156
[9]
Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute [J].
Ferrari, S ;
Bertoni, F ;
Mercuri, M ;
Picci, P ;
Giacomini, S ;
Longhi, A ;
Bacci, G .
ANNALS OF ONCOLOGY, 2001, 12 (08) :1145-1150
[10]
Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity [J].
Kaste, SC ;
Liu, T ;
Billups, CA ;
Daw, NC ;
Pratt, CB ;
Meyer, WH .
PEDIATRIC BLOOD & CANCER, 2004, 43 (07) :723-728